651 POSTER A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors

Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib

“…MET is known to be expressed in ASPS. [6][7] Immunohistochemistry for MET was negative in the tumor samples from both patients. This may be a result of problems in tissue preservation in the specimens, which were not obtained specifically for the study, and the tumors from these patients may in fact be MET dependent and MET expressing.…”

A phase 1 study of the c‐Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

“…Serious adverse events were uncommon (17; 5.1%) and included seven myelosuppression events in five patients and five gastrointestinal events in two patients. Dose‐limiting toxicities (DLTs) from single‐agent tivantinib included febrile neutropenia (2), thrombocytopenia (1), leukopenia (1), neutropenia (1), vomiting (1), dehydration (1), fatigue (1), mucosal inflammation (1), and palmar–plantar erythrodysesthesia syndrome (1) …”

“…Dose-limiting toxicities (DLTs) from single-agent tivantinib included febrile neutropenia (2), thrombocytopenia (1), leukopenia (1), neutropenia (1), vomiting (1), dehydration (1), fatigue (1), mucosal inflammation (1), and palmar-plantar erythrodysesthesia syndrome (1). [7][8][9][10] When considering the scope of pediatric and adolescent tumors affected by aberrant c-Met signaling, as well as the encouraging preliminary results of studies using c-Met inhibition strategies, 7,[42][43][44][45][46][47][48][49][50][51] exploration of c-Met inhibition in pediatric patients has emerged as an important focus of clinical investigation.…”